{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:43Z","timestamp":1787628103587,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014942","name":"Novartis Gene Therapies","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10198-024-01754-3","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:01:26Z","timestamp":1740103286000},"page":"1101-1110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands"],"prefix":"10.1007","volume":"26","author":[{"given":"Simon","family":"van der Schans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimma","family":"Velikanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Weidlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Howells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"1754_CR1","doi-asserted-by":"publisher","unstructured":"Kolb, J.T., Kissel, S.J.: Spinal muscular atrophy. Neurol. Clin. 33(4), 1\u201316 (2015). https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004","DOI":"10.1016\/j.ncl.2015.07.004"},{"key":"1754_CR2","unstructured":"Gezondheidsraad: Neonatale screening op spinale spieratrofie [Neonatal screening for spinal muscular atrophy] [Website in Dutch]. Accessed 20 December 2024. https:\/\/www.gezondheidsraad.nl\/documenten\/adviezen\/2019\/07\/23\/neonatale-screening-op-spinale-spieratrofie"},{"key":"1754_CR3","doi-asserted-by":"publisher","unstructured":"Gregoretti, C., Ottonello, G., Chiarini Testa, M.B., et al.: Survival of patients with spinal muscular atrophy type 1. Pediatrics. 131(5), e1509\u2013e1514 (2013). https:\/\/doi.org\/10.1542\/peds.2012-2278","DOI":"10.1542\/peds.2012-2278"},{"key":"1754_CR4","doi-asserted-by":"publisher","unstructured":"Kolb, S.J., Coffey, C.S., Yankey, J.W., et al.: Natural history of infantile-onset spinal muscular atrophy. Ann. Neurol. 82(6), 883\u2013891 (2017). https:\/\/doi.org\/10.1002\/ana.25101","DOI":"10.1002\/ana.25101"},{"key":"1754_CR5","doi-asserted-by":"publisher","unstructured":"Zerres, K., Rudnik-Sch\u00f6neborn, S., Forrest, E., et al.: A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J. Neurol. Sci. 146(1), 67\u201372 (1997). https:\/\/doi.org\/10.1016\/s0022-510x(96)00284-5","DOI":"10.1016\/s0022-510x(96)00284-5"},{"key":"1754_CR6","unstructured":"Zorginstituut Nederland (ZIN): Pakketadvies sluisgeneesmiddel onasemnogene abeparvovec (Zolgensma) bij de behandeling van spinale musculaire atrofie (SMA) [Package advice for the lock medicine onasemnogene abeparvovec (Zolgensma\u00ae) in the treatment of spinal muscular atrophy (SMA)] [Website in Dutch]. (2021). https:\/\/www.zorginstituutnederland.nl\/publicaties\/adviezen\/2021\/05\/06\/pakketadvies-sluisgeneesmiddel-onasemnogene-abeparvovec-zolgensma Accessed 5 June 2024"},{"key":"1754_CR7","unstructured":"G-Standaard databank: Z-index [Z-index] [Website in Dutch]. (2023). https:\/\/www.z-index.nl\/ Accessed 5 June 2024"},{"key":"1754_CR8","unstructured":"Spinraza (nusinersen): Prescribing information. Biogen. (2024). https:\/\/www.spinraza.com\/content\/dam\/commercial\/spinraza\/caregiver\/en_us\/pdf\/spinraza-prescribing-information.pdf Accessed 5 June 2024"},{"key":"1754_CR9","unstructured":"European Medicines Agency: Summary of product characteristics (Spinraza). (2024). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spinraza-epar-product-information_en.pdf Accessed 5 June 2024"},{"key":"1754_CR10","unstructured":"Horizonscan: Minister Bruno Bruins bereikt akkoord over vergoeding Spinraza [Minister Bruno Bruins reaches agreement on Spinraza compensation] [Website in Dutch]. (2018). https:\/\/www.horizonscangeneesmiddelen.nl\/nieuws\/spinraza-vergoed-voor-jonge-kinderen Accessed 5 June 2024"},{"key":"1754_CR11","unstructured":"Zorginstituut Nederland (ZIN): Risdiplam [Website in Dutch]. (2020). https:\/\/www.horizonscangeneesmiddelen.nl\/geneesmiddelen\/risdiplam-neurologische-aandoeningen-sma\/versie3?lang=nl Accessed 5 June 2024"},{"key":"1754_CR12","doi-asserted-by":"publisher","unstructured":"Dean, R., Jensen, I., Cyr, P., et al.: An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J. Mark. Access. Health Policy. 9(1), 1889841 (2021). https:\/\/doi.org\/10.1080\/20016689.2021.1889841","DOI":"10.1080\/20016689.2021.1889841"},{"key":"1754_CR13","doi-asserted-by":"publisher","unstructured":"Broekhoff, T.F., Sweegers, C.C.G., Krijkamp, E.M., et al.: Early cost-effectiveness of onasemnogene abeparvovec-xioi (Zolgensma) and nusinersen (spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios. Value Health. 24(6), 759\u2013769 (2021). https:\/\/doi.org\/10.1016\/j.jval.2020.09.021","DOI":"10.1016\/j.jval.2020.09.021"},{"key":"1754_CR14","unstructured":"Zolgensma (onasemnogene abeparvovec-xioi): Prescribing information. Novartis Gene Therapies, Inc. (2024). Accessed 20 December 2024. https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/zolgensma.pdf"},{"key":"1754_CR15","doi-asserted-by":"publisher","unstructured":"Delhove, J., Osenk, I., Prichard, I., et al.: Public acceptability of gene therapy and gene editing for human use: A systematic review. Hum. Gene Ther. 31(1\u20132), 20\u201346 (2020). https:\/\/doi.org\/10.1089\/hum.2019.197","DOI":"10.1089\/hum.2019.197"},{"key":"1754_CR16","doi-asserted-by":"publisher","unstructured":"Day, J.W., Finkel, R.S., Mercuri, E., et al.: Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec. Mol. Ther. Methods Clin. Dev. 21, 76\u201382 (2021). https:\/\/doi.org\/10.1016\/j.omtm.2021.02.014","DOI":"10.1016\/j.omtm.2021.02.014"},{"key":"1754_CR17","doi-asserted-by":"publisher","unstructured":"Lin, C.W., Kalb, S.J., Yeh, W.S.: Delay in diagnosis of spinal muscular atrophy: A systematic literature review. Pediatr. Neurol. 53(4), 293\u2013300 (2015). https:\/\/doi.org\/10.1016\/j.pediatrneurol.2015.06.002","DOI":"10.1016\/j.pediatrneurol.2015.06.002"},{"key":"1754_CR18","doi-asserted-by":"publisher","unstructured":"Keinath, M.C., Prior, D.E., Prior, T.W.: Spinal muscular atrophy: Mutations, testing, and clinical relevance. Appl. Clin. Genet. 14, 11\u201325 (2021). https:\/\/doi.org\/10.2147\/TACG.S239603","DOI":"10.2147\/TACG.S239603"},{"key":"1754_CR19","doi-asserted-by":"publisher","unstructured":"Dangouloff, T., Servais, L.: Clinical evidence supporting early treatment of patients with spinal muscular atrophy: Current perspectives. Ther. Clin. Risk Manag. 2, 15:1153\u20131161 (2019). https:\/\/doi.org\/10.2147\/TCRM.S172291","DOI":"10.2147\/TCRM.S172291"},{"key":"1754_CR20","unstructured":"Zorginstituut Nederland (ZIN): Pakketadvies sluisgeneesmiddel nusinersen (Spinraza\u00ae) voor de behandeling van spinale musculaire atrofie (SMA) [Package advice for lock medicine nusinersen (Spinraza\u00ae) for the treatment of spinal muscular atrophy (SMA)] [Website in Dutch]. (2018). https:\/\/www.zorginstituutnederland.nl\/publicaties\/adviezen\/2018\/02\/07\/pakketadvies-nusinersen-spinraza-voor-de-behandeling-van-spinale-musculaire-atrofie-sma Accessed 5 June 2024"},{"key":"1754_CR21","unstructured":"Zorginstituut Nederland: Guideline for economic evaluations in healthcare. (2016). https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2016\/06\/16\/guideline-for-economic-evaluations-in-healthcare Accessed 5 June 2024"},{"key":"1754_CR22","unstructured":"StatLine: Jaarmutatie consumentenprijsindex; vanaf 1963 (cbs.nl) [Annual change in consumer price index; from 1963] [Website in Dutch]. (2023). https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/70936NED\/table?fromstatweb Accessed 5 June 2024"},{"key":"1754_CR23","doi-asserted-by":"publisher","unstructured":"Bischof, M., Lorenzi, M., Lee, J., et al.: Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Curr. Med. Res. Opin. 37(10), 1719\u20131730 (2021). https:\/\/doi.org\/10.1080\/03007995.2021.1947216","DOI":"10.1080\/03007995.2021.1947216"},{"key":"1754_CR24","doi-asserted-by":"publisher","unstructured":"Pechmann, A., K\u00f6nig, K., Bernert, G., et al.: SMArtCARE\u2013 a platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J. Rare Dis. 14(1), 18 (2019). https:\/\/doi.org\/10.1186\/s13023-019-0998-4","DOI":"10.1186\/s13023-019-0998-4"},{"key":"1754_CR25","doi-asserted-by":"publisher","unstructured":"Finkel, R.S., Day, J.W., De Vivo, D.C., et al.: RESTORE: A prospective multinational registry of patients with genetically confirmed spinal muscular atrophy\u2013 rationale and study design. J. Neuromuscul. Dis. 7(2), 145\u2013152 (2020). https:\/\/doi.org\/10.3233\/JND-190451","DOI":"10.3233\/JND-190451"},{"key":"1754_CR26","doi-asserted-by":"publisher","unstructured":"Klug, C., Schreiber-Katz, O., Thiele, S., et al.: Disease burden of spinal muscular atrophy in Germany. Orphanet J. Rare Dis. 11(1), 58 (2016). https:\/\/doi.org\/10.1186\/s13023-016-0424-0","DOI":"10.1186\/s13023-016-0424-0"},{"key":"1754_CR27","doi-asserted-by":"publisher","unstructured":"Duenas, A.: Cost-minimization analysis. In: Gellman, M. (ed.) Encyclopedia of Behavioral Medicine, 1st edn. Springer, New York (2013). https:\/\/doi.org\/10.1007\/978-1-4419-1005-9_1376","DOI":"10.1007\/978-1-4419-1005-9_1376"},{"key":"1754_CR28","unstructured":"Gupta, Strategists: N\u2009=\u20091, a new paradigm. The value and challenges of precision medicine in the Netherlands. (2020). https:\/\/gupta-strategists.nl\/storage\/files\/Gupta-Strategists-n1_a-new-paradigm.pdf Accessed 5 June 2024"},{"key":"1754_CR29","unstructured":"Hakkaart-van Roijen, L., van der Linden, N., Bouwmans, C., et al.: Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg [Cost guide: Methodology of cost research and reference prices for economic evaluations in health care] [PDF in Dutch]. (2016). https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg\/Richtlijn%2Bvoor%2Bhet%2Buitvoeren%2Bvan%2Beconomische%2Bevaluaties%2Bin%2Bde%2Bgezondheidszorg%2B%2528verdiepingsmodules%2529.pdf Accessed 5 June 2024"},{"key":"1754_CR30","unstructured":"Pomp, M., Schoemaker, C.G., Polder, J.J.: Op weg naar maatschappelijke kosten-batenanalyses voor preventie en zorg: Themarapport Volksgezondheid Toekomst Verkenning 2014 [Towards social cost-benefit analyzes for prevention and care: Theme Report Public Health Future Outlook 2014] [Website in Dutch]. (2014). https:\/\/www.rivm.nl\/publicaties\/op-weg-naar-maatschappelijke-kosten-batenanalyses-voor-preventie-en-zorg-themarapport Accessed 5 June 2024"},{"key":"1754_CR31","doi-asserted-by":"publisher","unstructured":"Gauthier-Loiselle, M., Cloutier, M., Toro, W., et al.: Nusinersen for spinal muscular atrophy in the United States: Findings from a retrospective claims database analysis. Adv. Ther. 38(12), 5809\u20135828 (2021). https:\/\/doi.org\/10.1007\/s12325-021-01938-w","DOI":"10.1007\/s12325-021-01938-w"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-024-01754-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-024-01754-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-024-01754-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:22:05Z","timestamp":1753885325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-024-01754-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1007\/s10198-024-01754-3","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"9 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a cost comparison analysis and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Matthias Bischof and Anish Patel are employees of Novartis Gene Therapies, Inc., and own Novartis stock or other equities. Cornelis Boersma and Maarten Postma have received grants from Novartis Gene Therapies, Inc. Diana Weidlich and Ruth Howells are employees of Clarivate, which received funding for this analysis from Novartis Gene Therapies. Simon van der Schans and Rimma Velikanova report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}